Get the Stockscreener App
342.22
2.59%
-9.10
Pre-market:
343.02
0.80
+0.23%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $342.22, with a volume of 2.34M.
It is down -2.59% in the last 24 hours and up +2.79% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$351.32
Open:
$349
24h Volume:
2.34M
Relative Volume:
0.85
Market Cap:
$184.28B
Revenue:
$35.89B
Net Income/Loss:
$7.01B
P/E Ratio:
26.46
EPS:
12.9352
Net Cash Flow:
$11.54B
1W Performance:
-0.40%
1M Performance:
+2.79%
6M Performance:
+13.58%
1Y Performance:
+22.09%
1-Day Range:
$340.00
$351.95
1-Week Range:
$340.00
$353.25
52-Week Range:
$261.43
$353.25
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
342.22 | 189.18B | 35.89B | 7.01B | 11.54B | 12.94 |
|
LLY
Lilly Eli Co
|
1,023.80 | 930.38B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
227.72 | 540.74B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
218.67 | 395.77B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
147.87 | 292.08B | 54.45B | 14.42B | 17.15B | 7.333 |
|
NVO
Novo Nordisk Adr
|
60.33 | 279.45B | 46.69B | 15.29B | 9.25B | 3.4329 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
The Escalator: Regeneron, Lundbeck, Amgen and more - Medical Marketing and Media
AE Wealth Management LLC Purchases 18,798 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Faces 340B Legal Challenge As Stock Trades Near Analyst Views - simplywall.st
Missed Out on Eli Lilly? This GLP-1 Stock Could Be a Bargain Buy. - The Motley Fool
Tax Group Of The Year: Skadden - Law360
AMGEN ANNOUNCES WEBCAST OF 2025 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS - Yahoo Finance
Amgen Set to Report Q4 Earnings: What Investors Should Know - The Globe and Mail
Is Amgen Inc. stock a smart retirement pickEarnings Recap Summary & Community Trade Idea Sharing Platform - mfd.ru
Mirae Asset Global Investments Co. Ltd. Buys 47,958 Shares of Amgen Inc. $AMGN - MarketBeat
Truist Financial Corp Reduces Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen (NASDAQ:AMGN) Sets New 12-Month HighWhat's Next? - MarketBeat
Amgen Inc. $AMGN is Federated Hermes Inc.'s 10th Largest Position - MarketBeat
Amgen Inc. $AMGN Shares Sold by Bank of New York Mellon Corp - MarketBeat
Biosimilars Market Huge Growth in Future Scope 2026-2033 | Amgen Inc., Pfizer Inc., Samsung Bioepis Co., Ltd. - openPR.com
Is It Time To Reassess Amgen (AMGN) After Strong Multi Year Share Price Gains - simplywall.st
Amgen R&D EVP James Bradner On Upcoming Readouts And Doing Deals Around New Capabilities - Citeline News & Insights
Amgen Advances Teprotumumab Program With Completed Phase 1 Study in Healthy Chinese Volunteers - TipRanks
Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for - Finviz
J. Safra Sarasin Holding AG Has $69.74 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) to Release Quarterly Earnings on Tuesday - MarketBeat
Bernstein calls 2026 a “waiting year” for Amgen’s (AMGN) MariTide - MSN
Bernstein Calls 2026 a “Waiting Year” for Amgen’s (AMGN) MariTide - Insider Monkey
UBS Raises Price Target for Amgen (AMGN) Following Recent Analys - GuruFocus
Mutual of America Capital Management LLC Sells 3,290 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen's (NASDAQ:AMGN) 11% CAGR outpaced the company's earnings growth over the same five-year period - Yahoo Finance
Q3 Rundown: Amgen (NASDAQ:AMGN) Vs Other Therapeutics Stocks - Finviz
Intact Investment Management Inc. Cuts Stock Position in Amgen Inc. $AMGN - MarketBeat
Will 340B Lawsuit Over Drug Discounts Shift Amgen's (AMGN) Access Strategy And Investment Narrative? - simplywall.st
Whittier Trust Co. Acquires 39,111 Shares of Amgen Inc. $AMGN - MarketBeat
Sector Gamma AS Increases Position in Amgen Inc. $AMGN - MarketBeat
Investment House LLC Has $7.31 Million Stake in Amgen Inc. $AMGN - MarketBeat
Cullen Frost Bankers Inc. Decreases Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Commerzbank Aktiengesellschaft FI - MarketBeat
Amgen Inc. $AMGN Shares Sold by AMF Tjanstepension AB - MarketBeat
Amgen stock pulled back after a six-day run — here’s what investors watch next week - TechStock²
Amgen (AMGN) Downgraded Amid Competitive Pressures and Uncertain Future - GuruFocus
Y Intercept Hong Kong Ltd Grows Position in Amgen Inc. $AMGN - MarketBeat
Mn Services Vermogensbeheer B.V. Purchases 3,900 Shares of Amgen Inc. $AMGN - MarketBeat
Resona Asset Management Co. Ltd. Lowers Stake in Amgen Inc. $AMGN - MarketBeat
UniSuper Management Pty Ltd Acquires 6,911 Shares of Amgen Inc. $AMGN - MarketBeat
Teacher Retirement System of Texas Decreases Stake in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Strs Ohio - MarketBeat
Peering Into Amgen Inc's Recent Short Interest - Sahm
Assessing Amgen (AMGN) Valuation After The New Sagebrush 340B Lawsuit - simplywall.st
Amgen (AMGN) Faces Downgrade Amidst Promising Pipeline - GuruFocus
Amgen snaps after six straight sessions of gains - MSN
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock - Yahoo Finance
Lockheed Martin Investment Management Co. Makes New $2.62 Million Investment in Amgen Inc. $AMGN - MarketBeat
Analyst recommendations: Amgen, P&G, Spotify, Duolingo, Moderna… - marketscreener.com
Amgen (AMGN) Faces 340B Lawsuit: What Does Sagebrush Dispute Reveal About Its Stakeholder Strategy? - Yahoo Finance
Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):